Developer docs
API playgroundTry for free, no card

Search company profiles

Golden Helix

Full company profile

uuid00009nh

Namestring
Golden Helix
Legal namestring
Golden Helix, Inc.
Websiteurl
goldenhelix.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Golden Helix is a privately held bioinformatics software company founded in 1998 and headquartered in Bozeman, Montana. The company develops clinical-grade software for next-generation sequencing (NGS) variant analysis, interpretation, and reporting, serving diagnostic laboratories, hospitals, and genome centers. Its portfolio is anchored by the VarSeq Suite (clinical variant analysis with automated ACMG and AMP guideline workflows), VSWarehouse (enterprise genomic data management), and specialized modules including VSClinical, VSPGx for pharmacogenomics, VS-CNV for copy number variation detection, and VSPipeline for workflow automation, with Sentieon integrated for secondary alignment and variant calling.

The platform supports deployment on-premises, in private cloud, or fully air-gapped environments, with the company explicitly stating that patient data never leaves the customer's infrastructure. The software is developed under an ISO 13485:2016-certified quality management system, and VarSeq Suite is declared compliant with the EU In Vitro Diagnostic Regulation (IVDR) as a Class A medical device. Product development is supported by NIH SBIR grant funding, including a $400,000 award in September 2023 and a $2.2 million award in October 2025, both directed at pharmacogenomics capabilities.

Golden Helix monetizes primarily through annual term software licenses (Single Named User, Lab, Server/Cluster, and Site tiers) and introduced usage-based licensing alongside the VarSeq 3 and VSWarehouse 3 releases in November 2025. A separate Japan office in Nagoya supports Asia-Pacific distribution, and the company maintains a direct enterprise sales motion with "Request Evaluation" and "Request Demo" calls to action targeting clinical genomics buyers. The company has no publicly disclosed revenue, no venture capital funding, and operates with an estimated 11-50 employees across its two offices.

Short descriptiontext

Golden Helix is a private bioinformatics company, founded in 1998 in Bozeman, Montana, that develops ISO 13485-certified clinical variant analysis and interpretation software (VarSeq, VSWarehouse) for diagnostic laboratories, hospitals, and genome centers running NGS workflows.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBozeman, United States
HQ citystring
Bozeman
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical variant analysis, NGS interpretation software, genomic data management, bioinformatics platform, clinical reporting software
Industry3 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAMAC
Molecular & Genomic LIMS (NGS/Bioinformatics Lab Ops)
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Clinical Genomics Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Software Licenses
TypeSubscription Recurring
Description

Annual software licenses for VarSeq Suite, VSWarehouse, SVS, and GenomeBrowse. Licenses include Single Named User, Lab, Server, Cluster/Concurrent, and Site License options.

goldenhelix.com
2Usage-based Licensing
TypeUsage Based
Description

VarSeq 3 and VSWarehouse 3 introduced usage-based licensing options alongside traditional licensing models.

prnewswire.com
3Command Line Access
TypeSubscription Recurring
Description

Command line access add-on for VarSeq Suite, sold as an additional license component.

goldenhelix.com
4Professional Services
TypeProfessional Services
Description

Training, support, and professional services for implementation and optimization.

goldenhelix.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details7 tiers
1Single Named User License - For individual use on one computer
ModelSubscriptionBilling cadenceAnnual
Notes

Named user license for VarSeq Suite, SVS, and VSWarehouse. User login required. Cannot be shared.

goldenhelix.com
2Lab License - For kiosk-style use by any individual in organization
ModelSubscriptionBilling cadenceAnnual
Notes

Single computer installation for organization-wide use. Not for server or remote access deployment.

goldenhelix.com
3Server/Cluster License - Concurrent access for multiple users
ModelSubscriptionBilling cadenceAnnual
Notes

Software installed on server with designated concurrent user limits. Can be installed on workstations, servers, or cloud instances.

goldenhelix.com
4Site License - Multi-machine deployment
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Installation across multiple machines per Site License Agreement terms.

goldenhelix.com
5GenomeBrowse Standalone - Non-commercial research use
ModelFreemiumBilling cadenceMulti-year contract
Notes

Free for internal research purposes. Commercial use requires separate licensing agreement.

goldenhelix.com
6Usage-based Licensing
ModelUsage-basedBilling cadencePay-as-you-go
Notes

New licensing model introduced with VarSeq 3, supporting both small and large laboratories with flexible consumption.

prnewswire.com
7Evaluation License
ModelFreemiumBilling cadencePay-as-you-go
Notes

Free evaluation licenses available with defined evaluation period. Multiple users can request separate keys.

goldenhelix.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1VarSeq Suite
Description

Clinical variant analysis, interpretation, and reporting platform for genomic data.

goldenhelix.com
+5 more records
Core offering1 text field

Golden Helix sells clinical variant analysis and interpretation software for next-generation sequencing (NGS) workflows, anchored by the VarSeq Suite platform. The software supports germline, oncology, prenatal, and pharmacogenomics applications for diagnostic laboratories, hospitals, and genome centers, with flexible on-premises, private cloud, and air-gapped deployment models.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • VarSeq enables streamlined clinical variant analysis reducing laboratory workflow complexity
+1 more record
Product overview1 text field

Golden Helix offers a unified clinical genomics platform centered on VarSeq Suite, an integrated software system for clinical variant analysis and interpretation. The portfolio includes VSWarehouse for enterprise genomic data management and Sentieon for secondary analysis. Supporting products include SVS for research, GenomeBrowse for visualization, and specialized modules like VSClinical for ACMG/AMP clinical workflows, VS-CNV for copy number analysis, and VSPGx for pharmacogenomics. The platform supports deployment on-prem, in private cloud, or air-gapped environments, providing diagnostic laboratories, hospitals, and genome centers with scalable variant interpretation across germline, oncology, prenatal, and pharmacogenomics applications.

Product and service4 records
1VarSeq Suite
CategoryClinical Variant Analysis Software
Description

Clinical variant analysis, interpretation, and reporting platform for diagnostic laboratories, hospitals, and genome centers. Supports germline, oncology, prenatal, and pharmacogenomics workflows from targeted panels to whole genomes with integrated interpretation, automation, and data management capabilities.

2VSWarehouse
CategoryGenomic Data Management Software
Description

Enterprise genomic data management platform for scalable clinical and research programs. Provides server-based infrastructure for managing genomic data at scale across an organization.

3SNP & Variation Suite (SVS)
CategoryGenomic Research Software
Description

Research software for GWAS, PCA, association testing, and genomic analysis features. Intended for Research Use Only, not for diagnostic procedures.

4Golden Helix GenomeBrowse
CategoryGenomic Visualization Software
Description

Visualization tool for genomic data viewing and analysis, including BAM file visualization, coverage tracks, and variant display. Free for non-commercial internal research purposes.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Austrian Human Genetics Labs
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Multi-year strategic agreement with Austria's public medical genetics labs to enhance genomic diagnostics and research capabilities across six centers. Golden Helix's bioinformatics technologies are being integrated into Austria's healthcare infrastructure to support cancer and hereditary disease diagnostics.

prnewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

QIAGEN's QCI Interpret is one of the most direct commercial competitors in clinical variant interpretation for hereditary and oncology workflows. It is a much larger, publicly traded incumbent with broader product portfolio and global commercial reach.

TypeDirect peer
Description

SOPHiA Genetics offers a clinical genomics platform (SOPHiA DDM) used by hospitals and labs for variant interpretation across hereditary and somatic applications, with a strong European footprint that overlaps with Golden Helix's IVDR-positioned market.

TypeDirect peer
Description

Fabric Genomics provides AI-driven clinical interpretation software for hereditary disease and oncology NGS, directly competing with VarSeq in clinical variant classification and reporting workflows for diagnostic labs.

TypeDirect peer
Description

Congenica offers a clinical genomic data analysis platform for rare disease and inherited disorder interpretation, directly comparable to VarSeq's germline and hereditary disease workflows and target customer base of clinical labs.

TypeDirect peer
Description

GenomOncology provides clinical decision support and variant interpretation software for precision oncology workflows, directly overlapping with VarSeq's cancer/AMP-aligned clinical interpretation capabilities.

TypeDirect peer
Description

Velsera operates a clinical genomics platform supporting NGS analysis, interpretation, and data management for clinical and research customers, competing with both VarSeq and VSWarehouse in the clinical genomics software layer.

TypeEmerging player
Description

DNAnexus provides a cloud-based biomedical data analysis and clinical genomics platform, overlapping with Golden Helix on secondary and tertiary analysis infrastructure, though with a more cloud-native architecture model.

TypeBroad incumbent
Description

Illumina offers BaseSequence and DRAGEN-based secondary and tertiary analysis solutions, plus its own variant interpretation offerings, representing a vertically integrated incumbent competing in the same clinical variant analysis workflow that VarSeq addresses.

9PierianDx (now part of Tempus)
TypeDirect peer
Description

PierianDx, now part of Tempus, provided clinical genomic interpretation software for hereditary and somatic workflows, directly comparable to VarSeq's clinical interpretation capabilities and customer base of hospital and reference labs.

TypeOthers
Description

Sentieon is both a partner and adjacent provider of high-performance secondary analysis (alignment and variant calling) for NGS workflows integrated into Golden Helix's platform; it represents both a complementary technology and a potential competitor if it expands into tertiary interpretation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Golden Helix

Clinical Genomics Softwaregoldenhelix.com

Golden Helix is a private bioinformatics company, founded in 1998 in Bozeman, Montana, that develops ISO 13485-certified clinical variant analysis and interpretation software (VarSeq, VSWarehouse) for diagnostic laboratories, hospitals, and genome centers running NGS workflows.

What Golden Helix does

Golden Helix is a privately held bioinformatics software company founded in 1998 and headquartered in Bozeman, Montana. The company develops clinical-grade software for next-generation sequencing (NGS) variant analysis, interpretation, and reporting, serving diagnostic laboratories, hospitals, and genome centers. Its portfolio is anchored by the VarSeq Suite (clinical variant analysis with automated ACMG and AMP guideline workflows), VSWarehouse (enterprise genomic data management), and specialized modules including VSClinical, VSPGx for pharmacogenomics, VS-CNV for copy number variation detection, and VSPipeline for workflow automation, with Sentieon integrated for secondary alignment and variant calling.

The platform supports deployment on-premises, in private cloud, or fully air-gapped environments, with the company explicitly stating that patient data never leaves the customer's infrastructure. The software is developed under an ISO 13485:2016-certified quality management system, and VarSeq Suite is declared compliant with the EU In Vitro Diagnostic Regulation (IVDR) as a Class A medical device. Product development is supported by NIH SBIR grant funding, including a $400,000 award in September 2023 and a $2.2 million award in October 2025, both directed at pharmacogenomics capabilities.

Golden Helix monetizes primarily through annual term software licenses (Single Named User, Lab, Server/Cluster, and Site tiers) and introduced usage-based licensing alongside the VarSeq 3 and VSWarehouse 3 releases in November 2025. A separate Japan office in Nagoya supports Asia-Pacific distribution, and the company maintains a direct enterprise sales motion with "Request Evaluation" and "Request Demo" calls to action targeting clinical genomics buyers. The company has no publicly disclosed revenue, no venture capital funding, and operates with an estimated 11-50 employees across its two offices.

Golden Helix firmographics

Firmographics
Name
Golden Helix
Legal name
Golden Helix, Inc.
Website
https://goldenhelix.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
11–50 employees
Short description
Golden Helix is a private bioinformatics company, founded in 1998 in Bozeman, Montana, that develops ISO 13485-certified clinical variant analysis and interpretation software (VarSeq, VSWarehouse) for diagnostic laboratories, hospitals, and genome centers running NGS workflows.
Ownership category
akta.pro rank

Golden Helix industry classification

Industry
Product category
Clinical Genomics Software
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAMAC
Molecular & Genomic LIMS (NGS/Bioinformatics Lab Ops)
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Clinical variant analysis
  • NGS interpretation software
  • Genomic data management
  • Bioinformatics platform
  • Clinical reporting software

Where Golden Helix is headquartered

Location

Headquarters

HQ city
Bozeman
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Golden Helix business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Software Licenses: Annual software licenses for VarSeq Suite, VSWarehouse, SVS, and GenomeBrowse. Licenses include Single Named User, Lab, Server, Cluster/Concurrent, and Site License options.
  2. Usage-based Licensing: VarSeq 3 and VSWarehouse 3 introduced usage-based licensing options alongside traditional licensing models.
  3. Command Line Access: Command line access add-on for VarSeq Suite, sold as an additional license component.
  4. Professional Services: Training, support, and professional services for implementation and optimization.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualSingle Named User License - For individual use on one computer
SubscriptionAnnualLab License - For kiosk-style use by any individual in organization
SubscriptionAnnualServer/Cluster License - Concurrent access for multiple users
SubscriptionMulti-year contractSite License - Multi-machine deployment
FreemiumMulti-year contractGenomeBrowse Standalone - Non-commercial research use
Usage-basedPay-as-you-goUsage-based Licensing
FreemiumPay-as-you-goEvaluation License

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Golden Helix product offering

Product offering

Core offering

Golden Helix sells clinical variant analysis and interpretation software for next-generation sequencing (NGS) workflows, anchored by the VarSeq Suite platform. The software supports germline, oncology, prenatal, and pharmacogenomics applications for diagnostic laboratories, hospitals, and genome centers, with flexible on-premises, private cloud, and air-gapped deployment models.

Product overview

Golden Helix offers a unified clinical genomics platform centered on VarSeq Suite, an integrated software system for clinical variant analysis and interpretation. The portfolio includes VSWarehouse for enterprise genomic data management and Sentieon for secondary analysis. Supporting products include SVS for research, GenomeBrowse for visualization, and specialized modules like VSClinical for ACMG/AMP clinical workflows, VS-CNV for copy number analysis, and VSPGx for pharmacogenomics. The platform supports deployment on-prem, in private cloud, or air-gapped environments, providing diagnostic laboratories, hospitals, and genome centers with scalable variant interpretation across germline, oncology, prenatal, and pharmacogenomics applications.

Differentiator

Problem solved

Functional benefit

Brands

  • VarSeq Suite: Clinical variant analysis, interpretation, and reporting platform for genomic data.
  • VSWarehouse
  • SNP & Variation Suite (SVS)
  • GenomeBrowse
  • VSClinical
  • VSPGx

Products and services

  • VarSeq Suite Clinical variant analysis, interpretation, and reporting platform for diagnostic laboratories, hospitals, and genome centers. Supports germline, oncology, prenatal, and pharmacogenomics workflows from targeted panels to whole genomes with integrated interpretation, automation, and data management capabilities.
  • VSWarehouse Enterprise genomic data management platform for scalable clinical and research programs. Provides server-based infrastructure for managing genomic data at scale across an organization.
  • SNP & Variation Suite (SVS) Research software for GWAS, PCA, association testing, and genomic analysis features. Intended for Research Use Only, not for diagnostic procedures.
  • Golden Helix GenomeBrowse Visualization tool for genomic data viewing and analysis, including BAM file visualization, coverage tracks, and variant display. Free for non-commercial internal research purposes.

Quantifiable outcome

  • VarSeq enables streamlined clinical variant analysis reducing laboratory workflow complexity
  • +1 more outcomes

Companies that use Golden Helix

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Golden Helix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature8 records

Golden Helix partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Austrian Human Genetics LabscoreStrategic or Co-development Partner · 17 March 2026Multi-year strategic agreement with Austria's public medical genetics labs to enhance genomic diagnostics and research capabilities across six centers. Golden Helix's bioinformatics technologies are being integrated into Austria's healthcare infrastructure to support cancer and hereditary disease diagnostics.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Golden Helix competitors and assessment

Company assessment

Broad incumbents

  • QIAGEN (QIAgen Clinical Insight / QCI): QIAGEN's QCI Interpret is one of the most direct commercial competitors in clinical variant interpretation for hereditary and oncology workflows. It is a much larger, publicly traded incumbent with broader product portfolio and global commercial reach.
  • Illumina (BaseSpace / DRAGEN): Illumina offers BaseSequence and DRAGEN-based secondary and tertiary analysis solutions, plus its own variant interpretation offerings, representing a vertically integrated incumbent competing in the same clinical variant analysis workflow that VarSeq addresses.

Direct peers

  • SOPHiA Genetics: SOPHiA Genetics offers a clinical genomics platform (SOPHiA DDM) used by hospitals and labs for variant interpretation across hereditary and somatic applications, with a strong European footprint that overlaps with Golden Helix's IVDR-positioned market.
  • Fabric Genomics: Fabric Genomics provides AI-driven clinical interpretation software for hereditary disease and oncology NGS, directly competing with VarSeq in clinical variant classification and reporting workflows for diagnostic labs.
  • Congenica: Congenica offers a clinical genomic data analysis platform for rare disease and inherited disorder interpretation, directly comparable to VarSeq's germline and hereditary disease workflows and target customer base of clinical labs.
  • GenomOncology: GenomOncology provides clinical decision support and variant interpretation software for precision oncology workflows, directly overlapping with VarSeq's cancer/AMP-aligned clinical interpretation capabilities.
  • Velsera (formerly Seven Bridges Genomics): Velsera operates a clinical genomics platform supporting NGS analysis, interpretation, and data management for clinical and research customers, competing with both VarSeq and VSWarehouse in the clinical genomics software layer.
  • PierianDx (now part of Tempus): PierianDx, now part of Tempus, provided clinical genomic interpretation software for hereditary and somatic workflows, directly comparable to VarSeq's clinical interpretation capabilities and customer base of hospital and reference labs.

Emerging players

  • DNAnexus: DNAnexus provides a cloud-based biomedical data analysis and clinical genomics platform, overlapping with Golden Helix on secondary and tertiary analysis infrastructure, though with a more cloud-native architecture model.

Others

  • Sentieon: Sentieon is both a partner and adjacent provider of high-performance secondary analysis (alignment and variant calling) for NGS workflows integrated into Golden Helix's platform; it represents both a complementary technology and a potential competitor if it expands into tertiary interpretation.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Golden Helix social profiles

Digital presence

Golden Helix compliance and trust

Trust signal

Compliance2 records

Golden Helix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Golden Helix leadership team

Management profile

Number of profiles

Profiles1 record

Golden Helix funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Golden Helix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Golden Helix

What does Golden Helix do?

Golden Helix sells clinical variant analysis and interpretation software for next-generation sequencing (NGS) workflows, anchored by the VarSeq Suite platform. The software supports germline, oncology, prenatal, and pharmacogenomics applications for diagnostic laboratories, hospitals, and genome centers, with flexible on-premises, private cloud, and air-gapped deployment models.

Is Golden Helix a public or private company?

Golden Helix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Golden Helix founded?

Golden Helix was founded in 1998. It employs 11 to 50 people.

Where is Golden Helix based?

Golden Helix is headquartered in Bozeman, United States, in the North America region.

How does Golden Helix make money?

Four revenue lines are on record. Software Licenses are the primary driver. The others are usage-based Licensing, command Line Access and professional Services.

Who are Golden Helix's main competitors?

Broad incumbents on record are QIAGEN (QIAgen Clinical Insight / QCI) and Illumina (BaseSpace / DRAGEN). Direct peers are SOPHiA Genetics, Fabric Genomics, Congenica, GenomOncology, Velsera (formerly Seven Bridges Genomics) and PierianDx (now part of Tempus). DNAnexus is listed as an emerging player. Sentieon is listed as an others.

Does Golden Helix have an API?

No public API is recorded for Golden Helix.

What industry is Golden Helix in?

Golden Helix's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLACAMAC, Molecular & Genomic LIMS (NGS/Bioinformatics Lab Ops). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGolden Helix Partners with the Austrian Human Genetics Labs to Drive Advancements in Genomic MedicineGolden Helix, a US-based bioinformatics company, has signed a multi-year strategic agreement with Austria's six public medical genetics centers to integrate its Next-Generation Sequencing (NGS) diagnostic technologies into harmonized clinical workflows for cancer and hereditary disease diagnostics. The partnership builds on a decade-long relationship and will support both routine clinical testing and national-scale research projects including Austria's contribution to the Human Genome Project. The collaboration underscores Golden Helix's expansion in European precision medicine while providing Austrian healthcare institutions with advanced genomic capabilities.PR NewswireGolden Helix Launches VarSeq 3 and VSWarehouse 3Golden Helix, Inc. announced the release of VarSeq 3 and VSWarehouse 3, its next-generation platform for secondary and tertiary genomic analysis, featuring usage-based licensing, cloud deployment on AWS or Azure, and enhanced automation capabilities for clinical workflows. The platform integrates data from Genomenon's Mastermind databases, providing cited evidence for over 24 million variants and 25,000 genes to support clinical interpretation. The company positions the release as enabling labs of all sizes to implement precision medicine workflows with improved scalability and cost-effectiveness through a sample-based pricing model.LinkedIn#goldenhelixinc #precisionmedicine #ngs #pharmacogenomicsGolden Helix has been awarded an NIH SBIR Phase 2 Grant (2R44HG013456-02) to advance pharmacogenomics capabilities in their VarSeq Suite, which will help clinical labs and researchers deliver more precise, personalized treatment decisions. The company stated that this grant represents a milestone in their mission to improve patient outcomes through innovation in precision medicine.PR NewswireGolden Helix Receives a NIH SBIR Phase 2 GrantGolden Helix, Inc. was awarded a NIH SBIR Phase 2 Grant (2R44HG013456-02) to enhance its pharmacogenetic analytics as an integrated component of NGS-based genetic testing. The grant will fund the development of a pharmacogenomics enterprise platform designed to help clinicians identify actionable insights for individualized treatment decisions. The company has received a total of $7 million in NIH funding since 2017, with the PI being Dr. Andreas Scherer, President and CEO.YahooGolden Helix Receives a NIH SBIR Phase 2 GrantGolden Helix, Inc. announced it was awarded the NIH SBIR Grant 2R44HG013456-02 to develop a pharmacogenomics workflow for identifying biomarkers and treatment options as part of NGS-based genetic testing. The grant will enable the company to enhance its pharmacogenetic analytics capabilities, delivering more precise and scalable solutions for clinical practice. The PI of the grant, Dr. Andreas Scherer, President and CEO of Golden Helix, noted the company has received a total of $7 million in NIH funding since 2017.PR NewswireGolden Helix and Genomenon Announce Strategic Partnership to Advance Clinical DiagnosticsGolden Helix and Genomenon announced a partnership to integrate Genomenon's Mastermind Genomic Intelligence Platform and Cancer Knowledgebase into Golden Helix's VarSeq software suite. The integration provides curated germline and somatic content for variant interpretation, harmonized with public databases like ClinVar. The collaboration aims to reduce manual curation time and accelerate clinical decision-making.GoldenhelixEnterprise Genomic Analysis with VarSeq 3 & VSWarehouse 3Golden Helix announced the release of VarSeq 3 and VSWarehouse 3, introducing cloud-native deployment options for AWS and Azure along with expanded hybrid support. The update includes per-sample licensing models to assist smaller labs and new capabilities for long-read sequencing, such as repeat expansion detection. This release aims to provide high-throughput and diagnostic laboratories with scalable genomic analysis infrastructure.PR NewswireGolden Helix Launches Enterprise Genomic Analysis with VarSeq 3 and VSWarehouse 3Golden Helix announced VarSeq 3 and VSWarehouse 3, adding cloud-native deployment for AWS and Azure, hybrid/on-premise support, and per-sample licensing. The release includes long-read sequencing support for repeat expansions and secondary analysis integration. The company will demonstrate the tools at ESHG in Milan.PR NewswireGolden Helix Partners with the Danish Healthcare Regions to Drive Advancements in Genomic MedicineGolden Helix signed a multi-year agreement with all Danish healthcare regions to enhance genomic capabilities in cancer and hereditary disease diagnostics. The collaboration aims to integrate advanced genomic technologies into clinical workflows to improve patient outcomes. The partnership underscores Golden Helix's leadership in precision medicine.GoldenhelixGolden Helix PartnersGolden Helix maintains strategic partnerships with various technology firms and academic institutions to integrate its SNP & Variation Suite software with complementary genomic technologies. These collaborations include joint development efforts with entities such as GlaxoSmithKline, Illumina, and Sentieon to enhance bioinformatics analysis capabilities for genetic research.